Hill’s launches feline therapeutic diet for weight and mobility
Bottom line
Hill’s Pet Nutrition has launched Hill’s Prescription Diet Metabolic + j/d for cats, a new therapeutic formula intended to address two common comorbidities at once: excess weight and reduced mobility. In its April 30, 2026 announcement, Hill’s said the diet combines the company’s metabolic weight-management platform with its j/d joint-support nutrition, and is available through veterinarian recommendation. Hill’s says the food is designed for obese or overweight adult cats with compromised mobility, and cites clinical evidence that cats can show improved mobility in as little as one month while also supporting fat loss through metabolic activation. (hillspet.com)
Why it matters: For veterinary teams, the launch reflects a continued push toward combination therapeutic diets for patients that rarely present with a single nutrition-related problem. Hill’s points to 61% of cats evaluated by U.S. veterinary professionals in the 2022 Association for Pet Obesity Prevention report as overweight or obese, underscoring how often practices are managing body condition and osteoarthritis-related mobility concerns in parallel. A single diet that targets both may simplify recommendations, improve adherence for pet parents, and reduce the need to prioritize one condition over another during long-term management. (hillspet.com)
What to watch: Watch for how quickly clinics adopt the diet into feline weight-management and osteoarthritis protocols, and whether Hill’s publishes more detailed clinical data beyond its launch materials. (hillspet.com)
Hill’s Pet Nutrition is expanding its feline therapeutic portfolio with the launch of Hill’s Prescription Diet Metabolic + j/d, a combination diet aimed at cats that are both overweight and mobility-compromised. Announced April 30, 2026, the product brings together Hill’s established Metabolic and j/d platforms in a single veterinarian-recommended formula, positioning nutrition as a dual-purpose intervention for two chronic, often linked problems in feline practice. (hillspet.com)
The move fits a longer Hill’s strategy of building multi-benefit prescription diets for pets with overlapping conditions. The company has previously marketed combination diets in other categories, including formulas that pair weight management with urinary support, and industry coverage has framed the new feline launch as part of a broader demand for veterinary diets that address chronic disease complexity rather than single diagnoses in isolation. Hill’s parent company, Colgate-Palmolive, also highlighted the launch in first-quarter 2026 investor materials, suggesting it sees the product as a meaningful commercial and clinical addition to the Hill’s portfolio. (veterinarypracticenews.com)
According to Hill’s, the new food is formulated for adult cats that are obese or overweight and have compromised mobility. The company says the diet works with each cat’s metabolic response to help burn excess body fat and affect calorie utilization, while also supplying joint-supportive nutrition associated with the j/d line, including omega-3 fatty acids; Hill’s veterinary materials also reference glucosamine and chondroitin sulfate in the mobility platform. On product pages, Hill’s states that the diet provides complete and balanced maintenance nutrition for adult cats based on AAFCO feeding tests. (hillspet.com)
Hill’s promotional and investor materials say the formula is clinically shown to improve cats’ ability to run, jump, and play in as little as one month. That claim appears consistently across the company’s press release, product listing, and investor presentation, although publicly accessible launch materials reviewed here provide only limited detail on study design, sample size, or endpoints. That means veterinarians interested in how mobility was measured, what degree of weight loss was achieved, and which patient populations were included may still want fuller clinical evidence before making the diet a first-line recommendation for broad use. (hillspet.com)
Independent expert reaction tied specifically to this launch was limited in publicly available coverage, but the broader clinical rationale is familiar. Obesity remains a major issue in feline medicine, and Hill’s cited the Association for Pet Obesity Prevention’s 2022 report showing 61% of cats evaluated by U.S. veterinary professionals were overweight or obese. At the same time, mobility decline and degenerative joint disease are common in older cats, making the overlap clinically relevant. Industry reporting has therefore presented the launch less as a niche SKU addition and more as a practical response to a common real-world case mix in general practice. (hillspet.com)
Why it matters: For veterinary professionals, the biggest question isn’t whether obesity and mobility issues coexist, but whether a single-diet approach can improve compliance and outcomes in the exam room. Many feline patients with excess weight also have pain, stiffness, or reduced activity, which can make exercise-based weight-loss plans harder to execute and harder for pet parents to sustain. A diet that supports caloric management while also targeting joint health could make treatment plans easier to explain and follow, especially in households where therapeutic feeding adherence is already fragile. The tradeoff is that practices will still need to individualize recommendations based on concurrent disease, body condition scoring, pain control, and the cat’s willingness to accept the food. (hillspet.com)
The launch also reinforces how therapeutic nutrition companies are competing around multi-condition management, not just single-disease claims. Inference: that may matter commercially as clinics look for simpler protocols and pet parents look for fewer product changes. But it also raises the bar for evidence. If combination diets are going to replace more targeted stepwise approaches, veterinarians will likely want clearer published data on efficacy, case selection, and how these diets perform alongside analgesics, environmental modification, and structured weight-loss monitoring. (mordorintelligence.com)
What to watch: The next signals will be whether Hill’s releases fuller clinical datasets, whether distributors and clinics report strong uptake, and whether competitors answer with more multi-benefit feline therapeutic diets over the next 12 months. (hillspet.com)